The co-administration of streptozotocin (STZ) and nicotinamide (NA) can be used to induce T2DM animal models; this is because STZ causes pancreatic β-cell damage, whereas NA partially protects insulin-secreting cells against STZ damage (7–9). This evidence concerns the gene INS and type 2 diabetes mellitus.